| Names | |
|---|---|
| Preferred IUPAC name | 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid hydrochloride |
| Other names | Cipro Ciproxin Ciproflox Baycip Ciloxan |
| Pronunciation | /ˌsɪprəˈflɒksəsɪn haɪdrəˈklɔːraɪd/ |
| Identifiers | |
| CAS Number | 86393-32-0 |
| Beilstein Reference | Beilstein Reference: 58947 |
| ChEBI | CHEBI:5804 |
| ChEMBL | CHEMBL24 |
| ChemSpider | 109600 |
| DrugBank | DB00537 |
| ECHA InfoCard | 100.231.449 |
| EC Number | 60877-05-0 |
| Gmelin Reference | 1841425 |
| KEGG | D07741 |
| MeSH | D003987 |
| PubChem CID | 64741 |
| RTECS number | VY8750000 |
| UNII | 95OFP9Y43E |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C17H18FN3O3·HCl |
| Molar mass | 385.82 g/mol |
| Appearance | White to slightly yellowish crystalline powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -0.86 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 8.7 |
| Basicity (pKb) | 8.48 |
| Magnetic susceptibility (χ) | -72.2×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.698 |
| Dipole moment | 4.71 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 365.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1124.7 kJ/mol |
| Pharmacology | |
| ATC code | J01MA02 |
| Hazards | |
| Main hazards | May cause allergic skin reaction; may cause eye irritation; may be harmful if swallowed |
| GHS labelling | GHS07, GHS08 |
| Pictograms | health-hazard, exclamation-mark, environment |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. In case of accidental overdose, contact a physician or poison control center immediately. Store at controlled room temperature. Avoid excessive heat and humidity. Use as directed by your healthcare provider. |
| Flash point | > 235 °C |
| Lethal dose or concentration | LD₅₀ oral (rat): 5000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 5000 mg/kg (oral, rat) |
| NIOSH | WF2150000 |
| PEL (Permissible) | PEL (Permissible exposure limit) for Ciprofloxacin Hydrochloride: Not established. |
| REL (Recommended) | 500 mg every 12 hours |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Ciprofloxacin Enoxacin Ofloxacin Norfloxacin Lomefloxacin Danofloxacin Pefloxacin Levofloxacin Gatifloxacin Moxifloxacin |
| Section | Description |
|---|---|
| Product Name | Ciprofloxacin Hydrochloride |
| IUPAC Name | 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride |
| Chemical Formula | C17H18FN3O3·HCl |
| Synonyms & Trade Names | Ciprofloxacin HCl, Ciprofloxacini Hydrochloridum, Ciproxin, Cipro HC |
| HS Code & Customs Classification | 29334900 – falls under heterocyclic compounds with nitrogen hetero-atom; classification can vary by regulatory jurisdiction and should be cross-checked with the latest customs rulings for the intended market. |
Production-grade Ciprofloxacin Hydrochloride moves through several phases in manufacturing, with most plants focusing on reaction consistency, purity assurance, and impurity control. The main route typically starts with fluoroquinolone core synthesis, followed by piperazine ring incorporation and subsequent hydrochloride salt formation. Quality control insists on analytic confirmation of the chemical structure, uniformity in crystallinity, and phase identity. Reactor charging sequence, raw material phase quality, and solvent selection alter impurity spectrum and filtration ease; each creates batch-to-batch performance differences if not intensely monitored.
Raw material selection privileges pharmaceutical grade or validated intermediates for critical steps to minimize non-target byproducts. Environmental controls, like humidity regulation and temperature modulation, are set according to phase sensitivity and the stability of intermediates. Hydration state and particle size relate directly to salt form stability, affecting both filtration and drying rates in batch production.
Impurity generation follows predictable logic during synthesis. Major sources include incomplete reactions, reagent excess, or side reactions especially when the piperazine functional group is introduced: non-hydrolyzed esters, residual free base, and incorrect salt ratios can impact regulatory acceptance and downstream formulation. The presence or absence of specific trace impurities (e.g., desfluoro impurity, N-oxide, unreacted piperazine) is routinely quantified by manufacturer-level HPLC, LC-MS, or NMR, with detailed acceptance criteria often determined by QP standards or monograph compliance.
Every batch release depends on a conformance panel tailored to product grade—sterility for parenteral use, residual solvents for API compliance, or enhanced purity for injectable formulations. Hydrate state and granule morphology, both affected by the final crystallization and drying steps, contribute to product performance in compaction, blending, or tablet formulation. These differences ultimately require manufacturers to define, document, and routinely validate their specifications with a focus on end-use.
HS Code assignment is driven by molecular structure and end-use declaration; while 29334900 generally applies, regional tariff schedules and customs interpretations necessitate periodic review, especially for finished grade pharmaceuticals or imported intermediates. Batch documentation and traceability are mainstays during customs clearance, with audit-back obligations tied to each lot dispatched to market.
Ciprofloxacin hydrochloride, as produced across our industrial lines, typically presents as a crystalline powder. The color reflects purity levels, often ranging from white to pale yellow depending on the grade and synthesis route. No pronounced odor is present. The material’s melting point can display minor variation by lot and grade due to hydration state and purity; thermal behavior requires confirmation per batch, especially for regulated pharmaceutical grades. Boiling point is not a practical measure for this class of compound, as thermal degradation and decomposition dominate at elevated temperatures, rather than boiling. Flash point data is rarely relevant due to the chemical’s non-volatile, solid character. Bulk density and tap density are grade-specific, with finer-milled material produced for direct compression or high-surface area blending.
Ciprofloxacin hydrochloride demonstrates reliable chemical stability under controlled temperature and humidity. Grades designed for pharmaceutical use require tight moisture and light control, since photoreactivity and hydrolytic degradation will impact both appearance and assay. Reactivity towards strong acids, bases, and oxidants should be assessed during formulation development, as some excipients catalyze degradation. Degradation products and pathways are well characterized and must be monitored for regulated APIs.
Solubility in water is markedly influenced by pH, ionic strength, and the presence of co-solvents or mechanical agitation. In industrial solution-phase operations, solubility management is key to yield and crystallization control. Solution preparation for downstream pharmaceutical or veterinary formulation requires strict control of temperature, pH, and potential complexing agents, which may vary by customer process requirements. Batch-to-batch verification of solubility behavior ensures consistency.
Our technical department defines specifications according to target application: pharmaceutical API, veterinary, or industrial grades, each with distinct purity, impurity, and physical parameter standards. Exact values are set in the quality agreement and will vary to meet market or regulatory requirements.
Impurity levels are determined by process route, raw materials, and purification steps. Typical profiles include starting material residuals, side-products from cyclization or chlorination, and hydrolytic or photolytic degradants. Internal control limits follow compendial expectations for regulated markets; for custom-grade products, impurity acceptance aligns with customer risk assessment. Comprehensive monitoring includes process intermediates and potential genotoxins.
Release testing utilizes pharmacopoeial or in-house validated HPLC, titration, and spectroscopic methods. Method selection and qualification are grade-specific and based on final use and applicable regulatory guidance. Precision and robustness are assessed against international or regional documentation as required for customer or market.
Selection and qualification of raw materials directly affect process yield, impurity load, and cost structure. Only recognized and qualified vendors supply key raw materials, such as fluoroquinolone intermediates and reagents. Each input is evaluated for impurity burden and traceability.
Ciprofloxacin hydrochloride manufacturing follows a multi-step process, with cyclization, fluorination, and piperazinylation steps performed under close parameter control. Route selection is based on desired impurity profile and yield, as well as compliance with regulatory expectations for solvent and reagent use. Reagent and intermediate quality drive the rate of side-product formation and influence downstream purification costs.
Process control focuses on temperature, pH, and reagent addition rates. Inline testing for critical parameters limits batch failures. Purification stages often involve recrystallization, washing, and filtration, tailored by grade and end-use. For high-purity pharmaceutical grades, further treatment for residual solvents, colored impurities, and particle size distribution is applied.
End-product testing covers identification, clarity, purity, particle size, loss on drying, and residual solvent. Each lot passes full review before batch release. Batch consistency is maintained through validated control systems, with a traceable documentation trail for all critical production steps. Customer-specific requirements may introduce additional tests or tighter acceptance ranges.
Modifications commonly target the piperazine ring or carboxylic acid groups to generate salt forms or prodrugs for more tailored pharmacological profiles. Any reaction step must respect the molecule’s sensitivity to strong alkali, acid hydrolysis, and photochemical decomposition. Impurity formation during modification is carefully monitored, particularly for regulated pharmaceutical manufacturing.
Catalyst type, temperature, and solvent are selected to balance yield, selectivity, and manageable impurity formation. Water, alcohols, or mixed aqueous/organic systems remain preferred. Temperature and solvent control are process-specific, with safety margin maintained for batch scale-up.
Downstream modification supports the production of various salts, co-crystals, and combination formulations, particularly for veterinary or regional requirements. Each derivative demands specific control of by-product and residual solvent levels based on final market use.
Bulk storage requires low humidity, moderate temperature, and light protection; container compatibility with the hydrochloride salt drives material selection. Primary packaging must prevent moisture ingress and light exposure for pharmaceutical stocks; industrial grades for technical applications may tolerate broader conditions, but purity and physical stability still depend on these controls.
High-barrier packaging, such as sealed polyethylene-lined fiber drums or amber glass, offers strong performance. Compatibility is graded by batch storage and logistic duration. Packaging choice directly impacts substance stability during long-haul shipment or humid environments.
Shelf life reflects storage condition, grade, and production method. Observable degradation includes color change, loss of assay, and moisture-induced clumping. Periodic assessment for key attributes (potency, physical state, impurity breakthrough) forms the basis for ongoing lot release and retest period definition.
Safety classification follows regional GHS criteria according to available acute toxicity and irritation studies. Hazard and precautionary statements are matched to the observed risks during handling and conversion processes. Final application risk varies by formulation type and user contact level.
Handling guidance reflects the irritant potential and toxicological profile as determined in industrial-scale use. Most production operators work with engineering controls, PPE, and routine monitoring as justified by internal hazard assessments and customer-specific HSE requirements.
Data on acute and chronic toxicity, along with sensitization and irritation, are subject to public domain studies and disclosed regulatory assessment. Personnel exposure limits are determined case-by-case per region, customer, and final product form. Recommendations for safe handling and disposal are regularly reviewed as regulatory expectations or internal safety findings develop.
Manufacturers scale Ciprofloxacin Hydrochloride output according to pharmaceutical market requirements, typically using multi-purpose reactors with campaign-based planning. Shifts in API demand, allocation to regulated versus semi-regulated markets, and regulatory status of lines affect capacity benchmarks. Production scheduling is governed by workflow balance between fermentation-derived intermediates and final hydrochloride conversion. Most producers must coordinate supply chain timelines for quinolone intermediates, which occasionally constrains output during peak season or upstream disruption. Additional volume may be realized by switching lines between oxoquinolone APIs; this comes with cleaning validation and recertification requirements.
Operational lead times range widely. For standard grades, four to eight weeks from confirmed order to release is typical when upstream and compliance documentation are current. MOQ reflects batch sizing and downstream order book. GMP-compliant grades in pharma packaging follow stricter minimums tied to validated batch lots. Changes in packaging spec, analytical methods, or special release testing can extend lead times due to added internal and third-party evaluations.
Ciprofloxacin Hydrochloride packaging needs to control humidity and light exposure due to chemical sensitivity. Pharmaceutical-grade packaging involves double PE liners inside fiber drums or HDPE drums, with tamper-evident sealing and lot-level barcode traceability. For high-purity injectable or EU/US markets, packaging validation must address extractables, leachables, and secondary closure system stability. Lab-scale, kilo-scale, and sample packs meet R&D spec, subject to special release by QA.
Sea, air, and bonded transport modes are available, depending on destination and regulatory clearance. Export shipments into major regulated markets are matched to license, DMF, and COA requirements. Payment terms adhere to customer credit status and compliance checks, with LC or advance modes standard for new relationships. Incoterms, import-export license validation, and temperature/moisture tracking are set at the time of contract negotiation.
The dominating cost actors in Ciprofloxacin Hydrochloride production are the fluoroquinolone building blocks, solvent systems, and process consumables (e.g., carbon, silica, catalysts). Price volatility in key intermediates regularly stems from environmental regulation cycles in origin countries, particularly where upstream consolidation or chemical park shutdowns restrict throughput. Sourcing decisions prioritize compliance-assured, audit-traceable intermediates, often at a premium, to ensure batch-to-batch consistency. Changes in energy costs, solvent recycling rates, and labor or waste treatment contribute to quarter-on-quarter variance.
Price tiers reflect both grade and regulatory status. US/EU/JP GMP-compliant batches with supported DMF cost higher than non-regulated market material. Purity, residual solvent profile, and packaging certification all drive price brackets. For example, injectable grades require additional release assays and packaging validation, translating into elevated per-kilo costs. Larger or non-pharma packaging formats may present marginal economies of scale but seldom match the technical investment for regulated grades.
Grade differences stem from synthesis route, purification steps, and final QC acceptance criteria. High-purity or low-residual-solvent grades serve parenteral and oral solid dosages, where stricter standards for elemental impurities and microbiological content apply. Lower grades suit veterinary or less regulated formulation. Packaging certification aligns with pharmacopeial or end-use compliance—blister/bulk/sachets for finished dose integration lift costs due to the validated environment and traceability. ISO or GMP certification does not simply denote quality, but details full lifecycle control from raw material entry to customer delivery.
The Ciprofloxacin Hydrochloride API landscape features concentrated supply in India, China, and select European sites. China and India carry the bulk of upstream intermediate manufacturing, exposing both supply and pricing to regulatory and macroeconomic developments in those regions. US, EU, and Japan require DMF-backed, fully traceable batches, restricting market access and compressing supply diversity. The periodic disappearance or reentry of producers due to regulatory inspection cycles or plant upgrades can sharply move spot and contracted prices.
| Region | Industry Dynamics |
|---|---|
| US/EU/JP | High compliance cost; limited origin APIs accepted. Buyers prefer traceability and security of supply contracts. Recalls or warning letters prompt supply chain shifts and temporary price surges. |
| India | Major producer; balances both regulated and non-regulated exports. Pragmatic sourcing for intermediates but exposed to raw material volatility. Regulatory updates at domestic plants impact both global and local prices. |
| China | Dominant in intermediates; periodic output restriction from environmental policy and industrial clustering regulations. Seasonality affects both supply and price. |
Looking forward to 2026, major price influencers include regulatory stringency in intermediate-producing nations, rollout of new environmental laws in chemical production zones, consolidation among upstream suppliers, and changing DMF/CEP registration patterns. Based on current trends, stabilized prices may only follow major supply base investments or regulatory harmonization between origin and consumer markets. Short-term volatility is expected if environmental clampdowns or plant upgrades intersect with high demand cycles. Buyers will increasingly secure supply via forward contracts or multi-year pricing locked to compliance and quality parameters, not just volume.
Market data derives from published customs statistics, regulatory inspection updates, producer trade filings, and third-party market research. Manufacturer experience further incorporates direct supply chain feedback, change notification management, and batch production cost tracking. Pricing forecasts utilize rolling average calculation across procurement cycles, integrating major raw material futures and live contract adjustments.
Over the last year, several API parks in key Chinese production regions have faced temporary output reduction after environmental agency audits, creating price spikes for side-chain intermediates. New DMF/CEP applications and re-submissions from both India and China reflect shifting compliance baselines, particularly in response to US/EU audit findings. Manufacturers face higher validation and change control costs passed through to customers in regulated markets.
Continued tightening of solvent recovery regs in upstream plants and more frequent spot-inspections by national drug agencies drive periodic capacity adjustments. New guidance on nitrosamine impurity control has required extensive process review, additional impurity targeting in in-process QA, and increased frequency in product release testing, leading to temporarily higher release costs for affected lots. Import license changes, such as with the EU FMD implementation, have also required rapid adaptation in supply chain documentation packing and shipping validation.
To manage compliance risk and raw material cost swings, manufacturers source redundant intermediate options and maintain validated alternate route flexibility. Batch campaign planning prioritizes audit-preparedness and in-train process verification for both established and alternate supply streams. Additional investment in on-site QA labs and partnership with accredited third-party labs supports rapid release cycles and regulatory audit response. Real-time traceability and rapid deviation response serve as core strategies for consistent, market-ready batches in volatile regulatory or procurement climates.
Ciprofloxacin Hydrochloride is a synthetic fluoroquinolone antibacterial harnessed by healthcare formulators, veterinary industries, and research institutes. Pharmaceutical-grade material supports the production of finished dosage forms for human use, such as tablets, injections, and ophthalmic solutions. Veterinary-grade ensures suitability for oral and injectable formulations in livestock and companion animals. Non-pharma grades find pathways into diagnostic kits, laboratory reagents, and academic research protocols.
| Industry Field | Typical Grade Used | Key Parameters to Monitor |
|---|---|---|
| Human Pharmaceuticals | Pharmaceutical Grade (BP/EP/USP compliant) | Purity by HPLC, identified polymorphic form, residual solvents, limit tests for related substances, pyrogen status, endotoxins (for injectables) |
| Veterinary Medicine | Veterinary Grade | Purity by HPLC, acceptable impurity profile per local regulations, solvent residues, particle size (for suspensions) |
| Research/Diagnostics | Technical or Laboratory Grade | Assay by HPLC, minimal heavy metal content, solubility characteristics, absence of interfering substances for assay systems |
Production quality pivots on raw material integrity, chosen synthetic route, and grade-specific release criteria. Human pharmaceutical applications call for the tightest specification scope. Here, final assay, impurity profile, microbiological safety, and defined particle characteristics often undergo further scrutiny batch-to-batch. Veterinary and research uses center on assay and impurity patterns appropriate to local oversight and technical requirements, while not always matching human-grade thresholds.
End-use shaped by regulatory status and formulation route determines grade eligibility. Injectable or ophthalmic preparations trigger tighter controls on endotoxin and pyrogen status, mandating pharmaceutical grade.
Pharmaceutical grades must dovetail with standards such as BP, EP, or USP, checked for compliance through accredited quality systems. Veterinary and research applications operate under national or project-specific technical norms. Customers focused purely on research may select material that omits certain regulatory-driven attributes, if not essential for their process.
Human and veterinary drugs require characterization of impurities per pharmacopeial monographs, since persistence of synthetic by-products, degradants, or residual solvents impacts downstream safety and stability. Research-grade product tolerates a broader impurity pattern if the analytical goals permit.
Large-scale pharmaceutical production entails bulk quantities with batch-to-batch reproducibility and validated logistics chains for traceability. Smaller custom synthesizers or laboratories may access smaller batches, potentially even customized grades balanced for unique test environments or non-routine explorations.
Manufacturing teams review the candidate batch through a combination of in-house testing and customer validation. Trial use in intended processes—formulation benchwork, analytical protocols, pilot production—confirms real-world suitability before volume commitment. Lot release proceeds only after specification match, documented by internal quality control and, if needed, third-party laboratory verification.
Consistently supplying Ciprofloxacin Hydrochloride to global pharmaceutical markets requires a documented quality system. Our manufacturing facilities operate under a quality management system assessed and certified according to recognized international standards. This structure directs batch traceability, deviation investigation, and the validation of cleaning and control procedures. Surveillance audits and periodic re-certification sustain compliance and initiate continuous improvement.
Regulatory and pharmacopoeial conformity influences both production methods and the level of documentation maintained. Production batches destined for regulated markets adhere to the defined requirements set by major pharmacopeias and are subject to independent release testing. Certification scope varies: some grades carry a full Certificate of Suitability and confirmatory dossiers, others operate under local registration. These distinctions follow market, grade, and intended formulation route. Customers requiring proof of regulatory compliance can request access to inspection histories, qualification status, and product release documentation.
Product release is supported by a set of technical documents, tailored to grade and end use. Each delivered batch is accompanied by a Certificate of Analysis matching customer specifications or declared pharmacopoeial standards. Additional documentation may include stability data, impurity profiles, process validation summaries, and method validation packages. For direct regulatory submissions, our technical dossier support extends to confidential quality assessment files and prompt responses to deficiency letters. All documentation formats are systematically archived for retrieval, ensuring response accuracy in audits and regulatory queries.
Ciprofloxacin Hydrochloride production relies on the alignment of equipment capacity, validated process routes, and secured raw material contracts. Our production strategy balances buffer stockholding with a rolling manufacturing schedule driven by customer forecasts. This minimizes risk of supply interruption, especially for high-priority finished dosage plants. Clients can engage in both spot purchasing and long-term supply agreements. Volume and delivery frequency can be adjusted through framework orders, ensuring supply continuity in changing market conditions.
Core manufacturing assets focus on fermentation, isolation, and purification steps tailored to Ciprofloxacin Hydrochloride. Batch-to-batch consistency depends on the in-process control parameters, validated through continuous monitoring of critical steps: precursor integrity, crystallization, and drying. Diversified equipment pools enable simultaneous production of multiple grades. Redundant utilities and alternative raw material sources reinforce resilient supply. For custom grades or atypical delivery requirements, dedicated production windows can be negotiated.
Initial evaluation samples for Ciprofloxacin Hydrochloride can be supplied upon receipt of a formal application describing intended use, grade, and analytical requirements. The process often involves technical exchange to clarify target purity profile, desired particle parameters, and analytical method compatibility. Upon agreement, samples are released with full technical documentation, including CoA and, where relevant, residual solvent or microbiological data. For larger development projects, pilot-scale samples may be prepared under non-GMP or GMP protocols as requested.
Collaboration models range from standard supply contracts to joint-development schemes. For pharmaceutical manufacturers, this may mean integrated process optimization, joint impurity pathway mapping, or mutual technology transfer. Customers can opt for volume-based pricing, shipment on consignment, or production slot reservation. For technical support or regulatory filing needs, project teams coordinate closely with customer quality and regulatory affairs counterparts. This approach adapts to the pace of drug development, scale-up, or regulatory submission cycles while maintaining oversight over intellectual property and proprietary methods.
Process optimization for Ciprofloxacin Hydrochloride has shifted from yield maximization to impurity profiling, aiming for tighter control over A- and B-series impurities unique to certain quinolone intermediates. In the plant, analytical teams monitor the quinolone core synthesis, focusing on reducing chlorinated byproducts and residual solvents. Sourcing of 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline remains critical, as upstream quality directly influences post-purification requirements and downstream control of photodegradation-related impurities.
Beyond standard human formulations, veterinary market demand has increased for different salt forms and tailored particle size controls, especially for water-dispersible and injectable grades. R&D has monitored regulatory attention on environmental persistence of fluoroquinolones, with customer requests centering on low-residue grades suitable for aquaculture and food-producing animal applications. Application testing in the lab demonstrates that product consistency in polymorphic form and crystal habit can affect drug release rate profiles and suspension stability in specialized dosage forms.
Production lines have encountered challenges in managing genotoxic impurities, particularly in multi-purpose reactors with variable campaign histories. Inline real-time monitoring and tighter maintenance cycles have reduced cross-contamination risk, but the challenge persists particularly in older facilities. Teams have piloted continuous process routes to minimize hold times and expose the intermediate to fewer thermal cycles. Breakthroughs in chromatography allow for more granular separation and validation, which gives the quality department faster batch-release turnaround for grades destined for stringent regulated markets.
Global market demand during this period is expected to react to periodic regulatory updates, raw material price fluctuations, and continued scrutiny over antimicrobial resistance. In direct supply to finished dosage manufacturers, flexibility in grade customization remains a priority. Plants equipped to transition batch size and manage rapid product release (on-demand, smaller lots) gain an edge for markets responding to generic pressure and evolving pharmacopoeial specifications.
Adoption of automated quality analytics, such as online HPLC systems and digital batch records, enhances lot traceability and reduces human error in the review process. Manufacturing shifts away from legacy batch routes, with investments moving toward semi-continuous crystallization and solvent recycling. Production and maintenance teams report significantly higher reproducibility of crystal form, which links to superior filter cake handling and more predictable micronization performance.
Emphasis on solvent recovery, secondary waste minimization, and closed-loop systems has shaped both operating cost management and compliance positioning. Internal initiatives target reduction of halogenated byproducts through selective catalysis for side-chain coupling steps, with analytical labs validating the drop in hazardous waste streams. The technical department closely tracks regulatory discussion on discharge limits, preparing the site both for third-party audit expectations and for raw material chain-of-custody requests from pharmaceutical customers.
Inquiries from finished product manufacturers receive direct response from QC and application chemists familiar with the actual production campaign. Support focuses on adjusting particle size range within defined process parameters, clarifying typical impurity profiles for both standard and customized batches, and advising on process adaptation when switching to product from the plant’s specific synthesis route. Technical rationale, not just historical COA data, guides troubleshooting or proposed in-process control updates for customer-specific requirements.
For customers compounding with specific excipients or designing novel formulations, the technical service team reviews upstream manufacturing records for each relevant lot. Support covers dispersibility in various liquid media, solution clarity parameters, and the impact of crystal form variation on blending, tablet hardness, and dissolution rates. If downstream processing encounters unusual yield loss or instability, feedback loops tap into process data to correlate issues with prior micronization, granulation, or solvent residues.
Complaint handling draws on an integrated record of each batch’s synthesis, in-process controls, and analytical release data. Investigation protocols do not rely only on COA review but also include access to production logs, deviation records, and, if required, re-analysis by QC personnel who supervised the original lot. Adjustments or corrective actions are documented, with outcome measures tracked for recurrence prevention, not simply closure rate.
| Area | Manufacturer Approach |
|---|---|
| Raw Material Selection | Supplier qualification and traceability prioritized, especially for key fluorinated and piperazine starting materials. Impurity burden differs by grade. |
| Process Route Selection | Route determined by intended market, environmental compliance, and downstream impurity removal efficiency. Veterinary and human pharmaceutical standards are not always aligned. |
| Impurity Management | Genotoxic trace management tailored per customer’s regulatory market; batch-specific impurity profiling implemented for critical projects. |
| Batch Consistency | Lot reproducibility controlled by campaign history and reactor maintenance. Full traceability maintained on campaign-based lines for higher reliability. |
| Release Criteria | Final QC release includes all analytical data per specification and customer-specific requirements, not just standardized COA. |
As a chemical manufacturer, we produce ciprofloxacin hydrochloride through a tightly controlled synthetic process. Production takes place in dedicated GMP-compliant lines with full ownership of every critical stage—from raw material selection and reactor handling to crystallization and purification. Every shipment reflects a consistent particle profile, controlled moisture, and defined polymorphic forms. Finished lots undergo systematic in-process and end-product testing. This direct approach gives us technical command of output and traceability from synthesis to packed drum.
Ciprofloxacin hydrochloride supports a range of end-use products beyond generic oral tablets. Contract formulators and approved pharmaceutical facilities draw on our product for finished dose, veterinary health, and select bulk sterile compounding. Our bulk material undergoes validation to meet both oral and parenteral API requirements, allowing downstream customers to formulate with confidence. For research, diagnostics, and quality control labs, our material delivers reproducible assay results batch after batch.
No batch leaves our facility without passing comprehensive quality evaluation. Our in-house lab employs validated HPLC, UV-spectroscopy, and impurity profiling per compendial and client protocols. Every vessel and line receives documented cleaning and cross-contamination checks between runs. Change controls and deviation management systems underpin reliable process consistency, batch-to-batch. Certificates include full analytics, stability data, and origin documentation. Our investment in both QC systems and skilled operators supports consistent output regardless of production scale.
We pack ciprofloxacin hydrochloride in lined fiber drums or high-density PE containers sealed under controlled humidity, meeting standards for transport and storage stability. As a direct producer, we adjust fill weights and container sizes suited for industrial and commercial demands—ranging from pilot plant lots up to large-scale process runs. All export packaging complies with international transport regulations and comes with serialized seals for full chain-of-custody assurance.
Industrial and technical clients benefit from access to our technical team with expertise in chemical synthesis, pharmaceutical process support, and analytical method troubleshooting. We assist with regulatory filing support, including provision of drug master files and documentation suited to local agency applications. For process engineers scaling up or modifying formulations, our chemists offer on-site or remote troubleshooting rooted in live manufacturing experience. Process data, impurity profiles, and batch samples can be supplied for technical review.
Controlling every production stage yields cost transparency and stable lead times for manufacturers, authorized repackagers, and institutional buyers. Commercial teams value predictable performance, proven analytics, and real batch traceability. Our ownership of intellectual property and process scale ensures supply continuity against market disruptions. Warehousing at multiple logistic hubs reduces the risk of inland transit delays. Each year, our ciprofloxacin hydrochloride supports drug manufacturing, supply chain resilience, and competitive procurement for firms across the pharmaceutical value chain.
We produce Ciprofloxacin Hydrochloride bulk powder at industrial scale, and we know first-hand how critical proper storage is for maintaining both purity and usability. Uncontrolled storage conditions can lead to degradation, loss of potency, or unnecessary risk in production settings. For this reason, we insist on practices that reflect both international pharmaceutical expectations and our own in-house experience.
Our production team always emphasizes storage at a temperature below 30°C. This comes from both batch stability studies and our observations over extended inventory cycles. We do not recommend refrigeration, as moisture condensation can compromise product quality after removal from cold storage.
Humidity is an equally important variable. Ciprofloxacin Hydrochloride powder shows hygroscopic tendencies if left exposed. We use air-tight, moisture-barrier packaging at the point of manufacture and strongly advise keeping containers tightly sealed until use. Our warehouse policies support temperature and humidity monitoring to prevent caking or color changes, which can signal early degradation. A stable, cool, and dry warehouse—away from direct sunlight or localized heat sources—serves as the best defense against spoilage.
We validate a 36-month shelf life for our Ciprofloxacin Hydrochloride bulk powder from date of manufacturing, provided storage conditions remain stable and unopened factory packaging is used. Each production batch passes through regular retesting intervals during its commercial life cycle; we analyze for assay, impurity profile, and physical appearance to confirm suitability for pharmaceutical manufacturing and formulation. An intact original seal is critical for preserving this shelf life.
Our stability data complies with ICH guidelines for long-term and accelerated stability. Real-world deviations often result from inadequate air-conditioning or repeated unsealing and resealing of drums—practices that we caution against. In our facilities, material traceability and batch-level documentation help us track age, storage history, and retest status at all times. When our customers follow the same discipline, material integrity stays reliable throughout its assigned shelf life.
Oxygen and light exposure represent two lesser-discussed risks; our standard drums use opaque, light-resistant liners. Our technical team can advise on secondary containment and contingency plans if repackaging is necessary for manufacturing scale-up or facility transfer.
We encounter questions around partial use of bulk drums or repackaging for multi-site supply chains. Once a bulk container has been opened, we recommend using the material as soon as possible, and never exposing it to open air between uses. Desiccants, inert gas blanketing, and vacuum sealing after opening offer extra protection if split-drum consumption is unavoidable.
For companies facing extreme climates or inconsistent facility environments, investment in dedicated temperature and humidity controls pays off in reduced material loss. Our engineers collaborate with client QA teams to ensure that each transfer of material aligns with regulatory and practical requirements.
Any deviation from recommended storage and handling conditions can shorten usable shelf life or introduce risk into the finished drug product. Our production and logistics staff take this seriously, offering documentation, technical support, and practical advice directly from our factory. Preserving the quality of Ciprofloxacin Hydrochloride bulk powder is a joint effort from both manufacturer and user, and it starts with precise, consistent storage conditions.
Producing Ciprofloxacin Hydrochloride is a technical job that relies on expertise and robust process control. Our facility supplies this active pharmaceutical ingredient in several pharmaceutical grades, reflecting the official pharmacopoeias recognized globally. We manufacture Ciprofloxacin Hydrochloride compliant with the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and British Pharmacopoeia (BP) standards. The selection of these grades reflects direct feedback from formulation partners and contract manufacturers seeking qualification in distinct target markets.
Each grade has its own detailed testing requirements that cover aspects such as identification, purity profile, related substances, moisture content, and assay levels. Divergence between pharmacopoeia specifications sometimes brings subtle, yet significant, differences in impurity thresholds or analytical methods. We follow the precise analytical protocols for every batch, and our analytical documentation package supports successful downstream registration and audits. On request, our technical team can provide Certificate of Analysis and complete regulatory support.
In practice, choosing a specific grade is often driven by the final market of the finished product. Some customers exporting to the USA rely on our USP grade. Customers targeting the EU generally opt for the EP variant, and UK-based project managers ask for BP-grade compliance. Each grade receives a dedicated process stream to avoid cross-contamination and maintain the strict boundaries that regulators inspect during site audits. Our quality management team monitors every step, supported by process engineers and in-house analytical chemists.
Supplying bulk pharmaceuticals at the manufacturer level means optimizing output for consistency and cost-efficiency. We typically set our minimum lot size and minimum order quantity to balance production efficiency and customer convenience. For Ciprofloxacin Hydrochloride, the lowest practical minimum order quantity is often one drum, which equates to a net weight of 25 kilograms. Most commercial buyers find this volume sufficient for pilot batches or early stage formulation development. Our standard packaging features double-layer PE inner liners and fiber drums to maintain stability during shipment.
High-volume contracts, sometimes scaling to multi-metric-ton orders, run through automated lines equipped with sample in-process control stations. We manage long-term campaigns based on annual or semi-annual planning, ensuring uninterrupted supply for large generics projects and hospital-focused tenders. Since every production run undergoes meticulous QC, custom orders above the minimum are fully supported, provided production schedules and regulatory documentation are aligned.
Customers in regulated markets, including North America and Europe, face close scrutiny from authorities like the US FDA and EMA. These agencies demand traceability from raw material through to finished dose. By offering Ciprofloxacin Hydrochloride in multiple official grades, we enable customers to adhere to product registrations and respond to market opportunities without reformulating or renegotiating supply. Our own regulatory and technical support staff track new pharmacopoeial monographs and help customers implement changes fast, reducing disruption at the formulation stage.
Minimum order quantities anchor the economics of our manufacturing site. Operating a cGMP-compliant plant with validated cleaning, material traceability, and energy-intensive process steps means smaller runs are feasible mainly as exceptions. A clearly defined minimum secures on-time material dispatch while keeping costs predictable for formulators and finished-product manufacturers. Our direct supply approach means customers trace product back to a single source—avoiding ambiguity about batch history, specifications, or chain of custody.
Our technical team stands ready to advise on the available pharmacopoeial grades and support customers in selecting the right grade for their project. We recognize the push for higher standards in pharmaceutical manufacturing and commit to supporting every partner with transparency and technical precision.
Moving Ciprofloxacin Hydrochloride across borders brings plenty of regulatory scrutiny. We encounter strict controls in nearly every international transaction because this active pharmaceutical ingredient (API) belongs to a class considered vital for public health and carries potential for misuse or diversion if not properly managed. Each destination country shapes its own list of controlled substances and draws clear rules about how antibiotics enter and move through its borders. No matter the region, regulators demand persistent attention to these layers of compliance.
Isolation, drying, and purification of Ciprofloxacin Hydrochloride at industrial scale require considerable investment. But after handling the upstream chemistry, overcoming export restrictions can often turn into the most time-consuming step. We follow both origin and destination rules closely. Most authorities treat APIs for human use — especially antibiotics — as goods of high monitoring priority. That means the requirement for specific export licenses receives constant updates from both national drug controllers and customs bodies.
From our experience, shipping Ciprofloxacin Hydrochloride frequently invites export licensing controlled by Chinese NMPA (National Medical Products Administration), Indian CDSCO (Central Drugs Standard Control Organization), or the United States FDA, depending on production location. Our internal regulatory group checks current government bulletins before scheduling any international clearance. Paperwork errors or missing licenses can stop a shipment cold at the port, so our export managers verify compliance for every single batch headed out for overseas customers.
Border authorities expect a complete and organized set of export documents accompanying any shipment of Ciprofloxacin Hydrochloride. Commercial invoices, detailed packing lists, air waybills or ocean bills of lading, and certificates of analysis produced from our QA/QC lab all must fit together precisely. For pharmaceutical APIs, authorities and consignees often ask for GMP (Good Manufacturing Practice) certificates, Drug Master Files, and Certificates of Suitability, especially on first-time imports or tender-based projects. We store all analytical and production documentation for several years to answer retrospective audits by customs or regulatory offices.
Obtaining and updating Certificates of Pharmaceutical Product (COPP) issued by the local drug authority remains a critical part of the process. This document confirms manufacture at an approved site and lists regulatory status. Many countries in Latin America, the Middle East, and Africa ask for it before approving pharmaceutical imports. We coordinate with health agencies in the importing nation to bridge any documentation gaps. For example, some customs agencies mandate legalized or apostilled paperwork, which requires advanced planning and extra processing time on our end.
Every export package of Ciprofloxacin Hydrochloride we ship travels with an audit trail back to the production line. Our technical team works directly with logistics partners specializing in pharmaceutical transport. Refrigerated or controlled ambient shipping may be necessary if the end country’s climate regulations dictate. We update product labeling, material safety data sheets, and bulk transportation documentation any time a target market introduces a regulatory amendment. Our regulatory affairs managers proactively maintain communication with overseas registration agents and port health officers to anticipate sudden requirements or compliance inspection changes.
Shipping controlled APIs safely and legally means manufacturers must keep compliance as a daily priority. As the producer, we carry full responsibility for meeting all restrictions, securing the proper licenses, and delivering documentation down to the last page. Our teams invest heavily in regulatory intelligence and transparent customer support so international partners get reliable, lawful access to our pharmaceutical products — no exceptions, no gray zones.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
